

Part 1: Tuberculosis (TB) Screening Questionnaire (to be completed by student)

Name: _____

Date of birth: _____

Have you ever had close contact with persons known or suspected of having active TB disease? Yes No

Were you born in one of the countries or territories listed below that have a high incidence of active TB disease? (If YES, please **CHECK THE BOX** next to the country or territory below) Yes No

- | | | | | |
|---|---|--|---|---|
| <input type="checkbox"/> Afghanistan | <input type="checkbox"/> Comoros | <input type="checkbox"/> Indonesia | <input type="checkbox"/> Mozambique | <input type="checkbox"/> South Sudan |
| <input type="checkbox"/> Algeria | <input type="checkbox"/> Congo | <input type="checkbox"/> Iraq | <input type="checkbox"/> Myanmar | <input type="checkbox"/> Sri Lanka |
| <input type="checkbox"/> Angola | <input type="checkbox"/> Congo (Democratic Republic of) | <input type="checkbox"/> Kazakhstan | <input type="checkbox"/> Namibia | <input type="checkbox"/> Sudan |
| <input type="checkbox"/> Anguilla | <input type="checkbox"/> Côte d'Ivoire | <input type="checkbox"/> Kiribati | <input type="checkbox"/> Nauru | <input type="checkbox"/> Suriname |
| <input type="checkbox"/> Argentina | <input type="checkbox"/> Djibouti | <input type="checkbox"/> Korea (Democratic People's Republic of) | <input type="checkbox"/> Nepal | <input type="checkbox"/> Syria (Syrian Arab Republic) |
| <input type="checkbox"/> Azerbaijan | <input type="checkbox"/> Dominican Republic | <input type="checkbox"/> Korea (Republic of) | <input type="checkbox"/> Nicaragua | <input type="checkbox"/> Tajikistan |
| <input type="checkbox"/> Bangladesh | <input type="checkbox"/> Ecuador | <input type="checkbox"/> Kyrgyzstan | <input type="checkbox"/> Niger | <input type="checkbox"/> Tanzania (United Republic of) |
| <input type="checkbox"/> Belize | <input type="checkbox"/> El Salvador | <input type="checkbox"/> Lao People's Democratic Republic | <input type="checkbox"/> Nigeria | <input type="checkbox"/> Thailand |
| <input type="checkbox"/> Benin | <input type="checkbox"/> Equatorial Guinea | <input type="checkbox"/> Latvia | <input type="checkbox"/> Niue | <input type="checkbox"/> Timor-Leste |
| <input type="checkbox"/> Bhutan | <input type="checkbox"/> Eritrea | <input type="checkbox"/> Lesotho | <input type="checkbox"/> Northern Mariana Islands | <input type="checkbox"/> Togo |
| <input type="checkbox"/> Bolivia (Plurinational State of) | <input type="checkbox"/> Eswatini | <input type="checkbox"/> Liberia | <input type="checkbox"/> Pakistan | <input type="checkbox"/> Trinidad and Tobago |
| <input type="checkbox"/> Bosnia and Herzegovina | <input type="checkbox"/> Ethiopia | <input type="checkbox"/> Libya | <input type="checkbox"/> Palau | <input type="checkbox"/> Tunisia |
| <input type="checkbox"/> Botswana | <input type="checkbox"/> Fiji | <input type="checkbox"/> Lithuania | <input type="checkbox"/> Panama | <input type="checkbox"/> Turkmenistan |
| <input type="checkbox"/> Brazil | <input type="checkbox"/> French Polynesia | <input type="checkbox"/> Luxembourg | <input type="checkbox"/> Papua New Guinea | <input type="checkbox"/> Tuvalu |
| <input type="checkbox"/> Brunei Darussalam | <input type="checkbox"/> Gabon | <input type="checkbox"/> Madagascar | <input type="checkbox"/> Paraguay | <input type="checkbox"/> Uganda |
| <input type="checkbox"/> Burkina Faso | <input type="checkbox"/> Gambia | <input type="checkbox"/> Malawi | <input type="checkbox"/> Peru | <input type="checkbox"/> Ukraine |
| <input type="checkbox"/> Burundi | <input type="checkbox"/> Georgia | <input type="checkbox"/> Malaysia | <input type="checkbox"/> Philippines | <input type="checkbox"/> Uruguay |
| <input type="checkbox"/> Cabo Verde | <input type="checkbox"/> Ghana | <input type="checkbox"/> Maldives | <input type="checkbox"/> Qatar | <input type="checkbox"/> Uzbekistan |
| <input type="checkbox"/> Cambodia | <input type="checkbox"/> Greenland | <input type="checkbox"/> Mali | <input type="checkbox"/> Romania | <input type="checkbox"/> Vanuatu |
| <input type="checkbox"/> Cameroon | <input type="checkbox"/> Guam | <input type="checkbox"/> Marshall Islands | <input type="checkbox"/> Russian Federation | <input type="checkbox"/> Venezuela (Bolivarian Republic of) |
| <input type="checkbox"/> Central African Republic | <input type="checkbox"/> Guatemala | <input type="checkbox"/> Mauritania | <input type="checkbox"/> Sao Tome and Principe | <input type="checkbox"/> Viet Nam |
| <input type="checkbox"/> Chad | <input type="checkbox"/> Guinea | <input type="checkbox"/> Mexico | <input type="checkbox"/> Senegal | <input type="checkbox"/> Yemen |
| <input type="checkbox"/> China | <input type="checkbox"/> Guinea-Bissau | <input type="checkbox"/> Micronesia (Federated States of) | <input type="checkbox"/> Sierra Leone | <input type="checkbox"/> Zambia |
| <input type="checkbox"/> China, Hong Kong SAR | <input type="checkbox"/> Guyana | <input type="checkbox"/> Moldova (Republic of) | <input type="checkbox"/> Singapore | <input type="checkbox"/> Zimbabwe |
| <input type="checkbox"/> China, Macao SAR | <input type="checkbox"/> Haiti | <input type="checkbox"/> Mongolia | <input type="checkbox"/> Solomon Islands | |
| <input type="checkbox"/> Colombia | <input type="checkbox"/> Honduras | <input type="checkbox"/> Morocco | <input type="checkbox"/> Somalia | |
| | <input type="checkbox"/> India | | <input type="checkbox"/> South Africa | |

Source: World Health Organization Global tuberculosis report 2025. Accessed March 2026

Have you resided in or had frequent or prolonged visits* to one or more of the countries or territories listed above with a high incidence of TB disease (if YES, **CHECK THE BOX** next to the countries or territories above) Yes No

Have you been a resident and/or employee of high-risk congregate settings (e.g. correctional facilities, long-term care facilities, or homeless shelters)? Yes No

Have you been a volunteer or health worker who served clients who are at increased risk for active TB disease? Yes No

Have you ever been a member of any of the following groups that may have an increased incidence of latent M. TB infection or active TB disease: medically underserved, low-income, or abusing drugs or alcohol? Yes No

If the answer is YES to any of the above questions, Colorado College requires that you have Parts II and III completed by a health care provider.

If the answer to all the above questions is NO, no further documentation or testing is required. Please upload Part I to the student portal.

**The significance of travel exposure should be discussed with and evaluated by a health care provider.*

Part II: Clinical Assessment by Health Care Provider

Clinicians should review and verify the information in Part I. **Persons answering YES** to any of the questions in Part I are candidates for either the Interferon Gamma Release Assay (IGRA) (*preferred*) or the Mantoux tuberculin skin test (TST), unless a previous positive test has been documented.

History of positive IGRA blood test or TB skin test? Yes No
History of BCG Vaccination (if yes, consider IGRA, if possible) Yes No

A. TB Symptom Check

Does the student have signs or symptoms of active pulmonary tuberculosis disease? Yes No

If No, proceed to B or C

If yes, check symptoms below:

- Cough (especially if lasting 3 weeks or longer) with or without sputum production
- Coughing up blood (hemoptysis)
- Chest pain
- Loss of appetite
- Unexplained weight loss
- Night sweats
- Fever

Proceed with additional evaluation to exclude active tuberculosis disease including tuberculin skin testing, chest x-ray, and sputum evaluation as indicated.

B. Interferon Gamma Release Assay (IGRA)

Date obtained: _____ (specify method) QFT-GIT T-Spot Other _____

Result: Negative Positive Indeterminate Borderline (T-Spot only)

Date obtained: _____ (specify method) QFT-GIT T-Spot Other _____

Result: Negative Positive Indeterminate Borderline (T-Spot only)

C. Tuberculin Skin Test (TST)

*(TST results should be recorded as actual millimeters (mm) of induration, transverse diameter; if no induration, write "0". The TST interpretation should be based on mm of induration as well as risk factors)**

Date given: _____

Date read: _____

Result: _____ mm of induration

*Interpretation: Positive Negative

Date given: _____

Date read: _____

Result: _____ mm of induration

*Interpretation: Positive Negative

***Interpretation of guidelines**

Equal to or greater than 5 mm is positive

- Recent close contacts of an individual with infectious TB
- Persons with fibrotic changes on a prior chest x-ray, consistent with past TB disease
- Organ transplant recipients and other immunosuppressed persons (including receiving equivalent >15 mg/d of prednisone for >1 month)
- Persons infected with HIV

Equal to or greater than 10 mm is positive:

- Foreign born or travelers to the U.S. from high prevalence areas or who resided in one for a significant** amount of time
- People who use injection drug
- Mycobacteriology laboratory personnel
- Residents, employees, or volunteers in high-risk congregant settings
- Persons with medical conditions that increase risk of progression to TB disease including scoliosis, diabetes mellitus, chronic renal failure, certain types of cancers (leukemias and lymphomas, cancers of the head, neck, or lung), gastrectomy or jejunioileal bypass and weight loss of at least 10% below ideal body weight

**The significance of travel exposure should be discussed with and evaluated by health care provider

Equal to or greater than 15 mm is positive:

- Persons with no known risk factors for TB who, except for certain testing programs required by law or regulation, would otherwise not be tested

D. Chest x-ray (Required if TST or IGRA is positive)

Date of chest x-ray: _____

Result: Normal Abnormal

Part 3: Considerations of Treatment of Latent Tuberculosis Infection (LTBI)

All students with a positive IGRA or TST with no signs of active disease on chest x-ray should receive a recommendation to be treated for latent TB with appropriate medication. However, students in the following groups are at increased risk of progression from LTBI to TB disease and should be prioritized to begin treatment as soon as possible.

- Persons infected with HIV
- Persons recently infected with M. tuberculosis (within in the past 2 years)
- Persons with a history of untreated or inadequately treated TB disease, including persons with fibrotic changes on chest radiograph consistent with prior TB disease
- Persons receiving immunosuppressive therapy such as tumor necrosis factor-alpha (TNF) antagonists, systemic corticosteroids equivalent to/greater than 15 mg of prednisone per day, or immunosuppressive drug therapy following organ transplantation
- Persons with silicosis, diabetes mellitus, chronic renal failure, leukemia, or cancer of the head, neck, or lung
- Persons who have had a gastrectomy or jejunioileal bypass
- Persons weighing less than 90% of their ideal body weight
- Persons who smoke cigarettes or e-cigarettes and persons abuse drugs and/or alcohol

- Student agrees to receive treatment
- Student declines treatment currently

Health care provider signature

Date

Colorado College
Wellness Resource Center
719-389-7316 or wellness@coloradocollege.edu

Originally prepared by ACHA's Tuberculosis Task Force